Afficher la couverture 'A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. | Jobard, Elodie' en grand format
/5

0 avis

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.

Archive ouverte

Jobard, Elodie | Pontoizeau, Clément | Blaise, Benjamin J. | Bachelot, Thomas | Elena-Herrmann, Bénédicte | Trédan, Olivier

Edité par CCSD ; Elsevier -

International audience. Breast cancer (BC) displays a high heterogeneity from histology to prognosis, metastatic evolution and treatment responses. We report here a (1)H NMR-based metabolic phenotyping study aiming at identifying coordinated metabolic serum changes associated with advanced metastatic breast cancer (MBC) in comparison to the localized early disease (EBC). A model discriminating EBC and MBC patients is obtained (n=85: 46 EBC and 39 MBC), and validated with an independent cohort (n=112: 61 EBC and 51 MBC; 89.8% sensitivity, 79.3% specificity). We identify 9 statistically significant metabolites involved in this discrimination: histidine, acetoacetate, glycerol, pyruvate, glycoproteins (N-acetyl), mannose, glutamate and phenylalanine. This work illustrates the strong potential of NMR metabolic phenotyping for the diagnosis, prognosis, and management of cancer patients.

Consulter en ligne

Suggestions

Du même auteur

Batch profiling calibration for robust NMR metabonomic data analysis.

Archive ouverte | Fages, Anne | CCSD

International audience. Metabonomic studies involve the analysis of large numbers of samples to identify significant changes in the metabolic fingerprints of biological systems, possibly with sufficient statistical ...

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients

Archive ouverte | Jobard, Elodie | CCSD

The authors thank Lenaic Leroux for his assistance in recording the NMR data. . International audience. The mammalian target of rapamycin complex 1 (mTORC1) is an attractive target for HER-2 positive breast cancer t...

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma

Archive ouverte | Jobard, Elodie | CCSD

International audience. Background: Renal cell carcinoma is one of the most chemoresistant cancers, and its metastatic form requires administration of targeted therapies based on angiogenesis or mTOR inhibitors. Und...

Chargement des enrichissements...